A Phase 1 interventional study of insulin degludec/insulin aspart 30 and insulin degludec/insulin aspart 40 in Diabetes, Diabetes Mellitus, Type 1 and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 1 site in Germany. Open to male participants aged 18 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-10-23.
Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 642 studies in Diabetes Mellitus by Novo Nordisk A/S — 2 open to participants now, 3 under way, 1 of them phase 3. Diabetes Mellitus · Novo Nordisk A/S.
Among the 642 studies in Diabetes Mellitus by Novo Nordisk A/S, this one is the 297th largest by enrollment of the 494 interventional ones that give a count, is one of 53 that started in 2006, is one of 206 in phase 1, and was the 480th registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →2 of the 642 studies in Diabetes Mellitus by Novo Nordisk A/S are open now, in 2 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Germany
Ages 18–75
Novo Nordisk A/S · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.
This study: 18 Years to 69 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
642 studies; the count open now beside each. This study's row is marked.
First in 1989; this study’s year is marked. 53 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is below the median of 80 across 6,025 interventional studies indexed under Diabetes Mellitus.
Median enrollment 87 across the 494 interventional studies, 1,497 across the 148 observational. Of the 636 that completed or were terminated, 163 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
1 of the studies in Diabetes Mellitus by Novo Nordisk A/S that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07535307Novo Nordisk A/SInvestigating How NNC0487-0111 Regulates Insulin of Adults With Type 2 Diabetes | 2027-11-11 |
Add it to your calendar (.ics) → With an account.
Among the 642 studies in Diabetes Mellitus by Novo Nordisk A/S, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Europe. The aim of this trial is to compare different ratios of explorative formulations, not similar to the proposed commercial formulation, of IDegAsp (co-formulation of insulin degludec/insulin aspart and insulin aspart) with separately injected, simultaneous doses of insulin degludec (insulin 454), and insulin aspart, compared with biphasic insulin aspart 30 in male subjects with type 1 and type 2 diabetes mellitus.
Trial part 1 is a five-period cross-over trial with incomplete block-design in subjects with type 1 diabetes where each subject will be randomised to five out of the ten possible treatments. Each treatment consists of an injection of the insulin product followed by a euglycemic clamp with a washout period of 7-15 days between treatments.
Trial part 2 is a three-period cross-over trial with complete blockdesign in subjects with type 2 diabetes. Each treatment consists of an injection of the insulin product followed by a euglycaemic clamp with a washout period of 7-15 days between treatments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: insulin degludec/insulin aspart 30 · Drug: insulin degludec/insulin aspart 40 · Drug: insulin degludec/insulin aspart 50 · Drug: insulin degludec · Drug: insulin aspart · Drug: biphasic insulin aspart 30
Drug: insulin degludec/insulin aspart 40 · Drug: insulin degludec/insulin aspart 50 · Drug: biphasic insulin aspart 30
Single dose administrated subcutaneously (s.c., under the skin).
Single dose administrated subcutaneously (s.c., under the skin).
Single dose administrated subcutaneously (s.c., under the skin).
Single dose administrated subcutaneously (s.c., under the skin).
Single dose administrated subcutaneously (s.c., under the skin).
Single dose administrated subcutaneously (s.c., under the skin) as comparator.
Single dose administrated subcutaneously (s.c., under the skin).
Single dose administrated subcutaneously (s.c., under the skin).
Single dose administrated subcutaneously (s.c., under the skin).
Area under the insulin aspart concentration curve from 0-2 hours (for subjects with type 1 diabetes)
Time frame: 0-2 hours after dosing
Maximum glucose infusion rate divided by the average glucose infusion rate (for subjects with type 2 diabetes)
Time frame: 0-24 hours after dosing
Area under the glucose infusion rate curve
Time frame: 0-24 hours after dosing
Area under the serum insulin degludec concentration curve
Time frame: 0-96 hours after dosing
The record gives a start of Sep 2006, a primary completion of Feb 2007 and a completion of Feb 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.